Ascendis Pharma A/SASND

那斯達克 · USD
210.16
+8.92
(+4.43%)
收盤 12/12 04:59 (UTC+8)
12/12 04:59 (UTC+8)

財務數據

損益表

loading
載入中...
icon
  • 0.47
  • 0.48
  • 1.38
  • 0.96
  • 0.36
  • 0.58
  • 1.74
  • 1.01
  • 1.58
  • 2.14
icon
  • 41.10
  • 1.35
  • 186.68
  • -30.36
  • -62.46
  • 60.66
  • 200.72
  • -41.95
  • 56.55
  • 35.17
  • icon
    營業收入(億)
  • icon
    季增長率(%)
單位:美元千元
年季
2025/Q3
2025/Q2
2025/Q1
2024/Q4
2024/Q3
2024/Q2
2024/Q1
2023/Q4
2023/Q3
2023/Q2
營業收入淨額
213,634
158,045
100,954
173,916
57,833
35,998
95,894
137,702
48,034
47,393
營業成本
22,35431,44717,51714,02311,20111,4657,56919,4577,38812,929
營業毛利
191,280
126,598
83,437
159,893
46,632
24,533
88,325
118,245
40,646
34,464
營業費用
180,283179,549184,195159,510143,375157,790137,470154,856175,053175,302
研發費用
66,87971,98886,60379,29673,54483,47870,68790,881111,439105,021
推銷及管理費用
111,687105,71095,64878,78168,12972,29566,78363,97562,51370,281
非經常性項目費用
----------
其他營業費用
----------
營業利益
10,997
-52,951
-100,758
383
-96,743
-133,257
-49,145
-36,611
-134,407
-140,838
其他收入及費用
----------
利息費用
19,72133,01844,786-4,98416,05919,62477,1618,42524,5199,334
稅前純益
-57,372
-35,007
-93,565
-37,384
-98,178
-109,151
-128,527
-81,088
-161,578
-121,862
所得稅
3,6173,8481,0611,0851,0202292,5085,790645-429
稅後純益
-60,989
-38,855
-94,626
-38,469
-99,198
-109,380
-131,035
-86,878
-162,223
-121,433
基本每股稅後盈餘(元)
-1.00-0.64-1.58-0.64-1.72-1.91-2.30-1.54-2.88-2.16
稀釋每股稅後盈餘(元)
-1.00-0.82-1.58-0.64-1.72-2.21-2.30-1.54-2.88-2.16
基本平均股數(千股)
60756.0060454.0060018.0059785.0057535.0057345.0056883.0056560.0056272.0056218.00
稀釋平均股數(千股)
60756.0063911.0060018.0059785.0057535.0060802.0056883.0056560.0056272.0056218.00
還原基本每股稅後盈餘(元)
-1.00-0.64-1.58-0.64-1.72-1.91-2.30-1.54-2.88-2.16
還原稀釋每股稅後盈餘(元)
-1.00-0.82-1.58-0.64-1.72-2.21-2.30-1.54-2.88-2.16
還原基本平均股數(千股)
60,75660,45460,01859,78557,53557,34556,88356,56056,27256,218
還原稀釋平均股數(千股)
60,75663,91160,01859,78557,53560,80256,88356,56056,27256,218
EBITDA(千元)
-33,6322,319-44,234-37,893-77,745-85,139-46,889-67,686-132,316-107,883

大家都在看

HOT